SCHEMBL8745764

SCHEMBL8745764

Cc1ccc2nc(C#N)ccc2c1Br

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.42
KDM4E B2RXH2 3/20 0.32
GRM5 P41594 1/20 0.32
KCNH2 Q12809 1/20 0.32
ALDH1A1 P00352 4/20 0.32
TNF P01375 2/20 0.32
CTSB P07858 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
SOS2 Q07890 1/20 0.31
CYP11B1 P15538 1/20 0.30
CYP11B2 P19099 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30
HTT P42858 1/20 0.30
NCOA1 Q15788 1/20 0.30
HIF1A Q16665 1/20 0.30
NCOA3 Q9Y6Q9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11986214 0.80 NQO1 (0.41) NQO1KDM4EALDH1A1CTSBPOLB
SCHEMBL8745771 0.79 ESR1 (0.51) NQO1KDM4EGRM5KCNH2ALDH1A1
SCHEMBL14573267 0.76 ALDH1A1 (0.51) KDM4EALDH1A1ESR1ESR2LMNA
SCHEMBL25873382 0.76 NQO1 (0.40) NQO1KDM4EALDH1A1CTSBSMN1; SMN2
SCHEMBL25314520 0.75 NQO2 (0.44) NQO1POLB
SCHEMBL24206916 0.74 NQO1 (0.39) NQO1ALDH1A1CTSB
SCHEMBL2981097 0.74 NQO1 (0.38) NQO1KDM4EALDH1A1SOS2LMNA
SCHEMBL29560656 0.74 NQO1 (0.38) NQO1KDM4EALDH1A1SOS2LMNA
SCHEMBL16914971 0.73 L3MBTL1 (0.44) NQO1KDM4EALDH1A1
SCHEMBL14573271 0.73 KDM4E (0.42) KDM4EALDH1A1ESR1ESR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2018-08-09 US disclosed
US-20170143694-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2017-05-25 US disclosed
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-8623892-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-01-07 US disclosed
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-07-18 US disclosed
US-8389543-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2013-03-05 US disclosed
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KDM4E 3322/4885GRM5 1351/4885
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KDM4E 3322/4885GRM5 1351/4885
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KDM4E 3322/4885GRM5 1351/4885
US-20170143694-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KDM4E 3322/4885GRM5 1351/4885
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KDM4E 3322/4885GRM5 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.